Insulet stock gains support from Bank of America stake and strong Q1 2026 figures

Published on 09/20/2026 at 19:19 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Insulet stock is underpinned by Bank of America Corp DE’s purchase of 426,409 shares disclosed on September 20, 2026, alongside solid Q1 2026 results with revenue of USD 761.7 million. Analysts expect full-year 2026 EPS of about 6.51, with a consensus price target near USD 195.40.

Reinraum-Fertigung Insulet – Medizintechnik-Mitarbeiter montieren Insulinpumpen-Pods an Edelstahlbänken — Insulet Reinraum in der Medizintechnik: Mitarbeiter montieren schlauchfreie Insulin-Pods an Edelstahlbänken, ISIN US45784P1012, Illustration mit AI erstellt.

Insulet Corporation stock (ISIN US45784P1012) is drawing investor attention after a fresh filing showed Bank of America Corp DE accumulating 426,409 shares, while the diabetes technology company continues to benefit from strong Q1 2026 results and Omnipod 5 adoption as of September 20, 2026.

Bank of America position and analyst consensus

According to MarketBeat on September 20, 2026, Bank of America Corp DE disclosed that it bought 426,409 shares of Insulet Corporation, reinforcing institutional interest in the stock.

In the same overview, MarketBeat reports that Insulet presently has a consensus rating of Hold from research analysts and an average price target of USD 195.40, framing expectations for the share price over the coming months.

As of the latest MarketBeat snapshot referenced in that filing, Insulet shares opened at USD 140.60 on the most recently completed trading day, providing a reference level that is noticeably below the consensus target of USD 195.40 and indicating upside of roughly 39 percent between the opening price and the average analyst objective.

Q1 2026 results and Omnipod momentum

A separate sector report highlights that Insulet’s Q1 2026 results exceeded analyst forecasts, with revenue of USD 761.7 million and earnings per share of USD 1.42, supported by robust demand for the Omnipod 5 insulin delivery system.

According to an analysis of the diabetes technology and medical devices market published on September 20, 2026 by IndexBox, Insulet’s Q1 2026 revenue of USD 761.7 million and EPS of USD 1.42 came in above analyst expectations, illustrating that the company is converting its Omnipod 5 rollout into tangible top-line and bottom-line growth.

The same IndexBox report notes that despite the strong Q1 2026 performance, weaker-than-expected Q2 guidance and a voluntary device correction have weighed on sentiment, reminding investors that execution and product reliability remain key risk factors for Insulet’s growth story.

Guidance, risks and full-year expectations

Per the MarketBeat overview dated September 20, 2026, Insulet has set its fiscal year 2026 earnings guidance in a range that is summarized at approximately USD 6.46 per share, with analysts on average expecting EPS of roughly USD 6.51 for the current year.

This guidance range implies that the company anticipates maintaining profitability throughout 2026, even as it navigates the operational impact of the voluntary device correction highlighted by IndexBox, which described weaker Q2 2026 guidance and the correction as important near-term constraints.

For investors, the combination of Bank of America’s 426,409-share purchase, consensus EPS expectations around USD 6.51 for fiscal 2026, and an average price target of USD 195.40 forms a picture of a company that is fundamentally profitable and still viewed with moderate optimism, but with risks tied to product issues and guidance cuts that could limit multiple expansion.

Insulet stock and trading context

On the most recent completed trading day before September 20, 2026, Insulet stock opened at USD 140.60 on Nasdaq, according to MarketBeat data, a level that remains significantly below the average analyst price target of USD 195.40 and therefore indicates that the shares are trading at a substantial discount to consensus expectations.

If Insulet were to reach the average analyst target of USD 195.40 from the USD 140.60 opening level reported in the MarketBeat filing, this would represent a gain of around USD 54.80 per share, which is roughly 39 percent upside, underscoring the sensitivity of future returns to the company’s ability to sustain Omnipod growth and resolve device correction issues.